GPT and cirrhosis of liver: To investigate the therapeutic effect of UCMSC treatment for more than 4 weeks in patients with liver failure and patients with liver cirrhosis, we compared the outcome of group A with that of group C. The median decreases in serum TBIL, ALT, AST, and PTA values and MELD scores at all postbaseline time points were not significantly different between group A and group C (Fig. 5a) (Table 4).